More >>

Welcome To Iconic Therapeutics

Iconic Therapeutics, Inc., an Atlanta, Georgia based biopharmaceutical company, has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1™.  hI-con1  binds tissue factor   More »

Molecular Structure homepage_molecular_structure

PHASE  1  STUDY

Iconic recently completed a prospective, multi-center study in the United States evaluating the safety and tolerability of a single intravitreous injection of 60µg, 150µg or 300µg of hI-con1 in 18 subjects (6 per dosing cohort) with wet AMD. Subjects could be treatment naïve or have been on prior therapy. All patients were followed for six months. No dose limiting toxicities were observed and there was evidence of biologic activity. Further studies are planned.